The complexity of the syphilis diagnostic pipeline has increased significantly as new technologies move from the research phase to clinical application. Historically, the market was split simply between treponemal and non-treponemal tests, but 2026 has introduced a far more nuanced segmentation. Today, the market is categorized by technology, including chemiluminescence immunoassays (CLIA),...